177Lu-based therapies, such as 177Lu-DOTATATE for neuroendocrine tumors and 177Lu-PSMA for prostate cancer, have demonstrated remarkable therapeutic effects by selectively targeting tumors that overexpress peptide receptors or prostate-specific membrane antigen (PSMA) [24,25,26]. Here, FOLH1 is linked to prostate carcinoma.